Bupropion/zonisamide
From Wikipedia, the free encyclopedia
Combination of | |
---|---|
Bupropion | Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist |
Zonisamide | Sulfonamide anticonvulsant |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.[1][4][5]
See also[]
- Naltrexone/bupropion
References[]
- ^ a b c "Bupropion/Zonisamide - AdisInsight".
- ^ Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
- ^ Empatic Obesity Drug Information and News
- ^ Ioannides-Demos LL, Piccenna L, McNeil JJ (2011). "Pharmacotherapies for obesity: past, current, and future therapies" (PDF). Journal of Obesity. 2011: 179674. doi:10.1155/2011/179674. PMC 3006492. PMID 21197148.
- ^ Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID 23312373. S2CID 21974224.
| |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Calcium |
| ||||||||||||||||||||||||
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |
Monoamine reuptake inhibitors | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DAT (DRIs) |
| ||||||||||||||
NET (NRIs) |
| ||||||||||||||
SERT (SRIs) |
| ||||||||||||||
VMATs |
| ||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |
Nicotinic acetylcholine receptor modulators | |||||
---|---|---|---|---|---|
nAChRs |
| ||||
Precursors (and prodrugs) |
| ||||
See also: Receptor/signaling modulators • Muscarinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators |
This drug article relating to the nervous system is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Abandoned drugs
- Anorectics
- Antiobesity drugs
- Calcium channel blockers
- Carbonic anhydrase inhibitors
- Combination drugs
- Norepinephrine releasing agents
- Norepinephrine reuptake inhibitors
- Nicotinic antagonists
- Sodium channel blockers
- Nervous system drug stubs
Hidden categories:
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs that are a combination of chemicals
- All stub articles